Zepbound (Tirzepatide) in 17-Year-Olds
Zepbound is now appropriate for 17-year-olds with type 2 diabetes based on the recently completed SURPASS-PEDS trial, which demonstrated superior glycemic control and BMI reduction in youth aged 10 to <18 years. 1
Evidence for Use in Adolescents
The SURPASS-PEDS trial (2025) provides the strongest and most recent evidence for tirzepatide use in this age group 1:
- Enrolled 99 participants aged 10 to <18 years (mean age 14.7 years) with type 2 diabetes inadequately controlled on metformin and/or basal insulin 1
- Demonstrated 2.28% greater HbA1c reduction compared to placebo at 30 weeks (tirzepatide reduced HbA1c by 2.23% versus 0.05% increase with placebo; p<0.0001) 1
- Sustained glycemic efficacy through 52 weeks of treatment 1
- Significant BMI reductions of 7.4% (5 mg dose) and 11.2% (10 mg dose) versus 0.4% with placebo at 30 weeks 1
Safety Profile in Adolescents
The safety data from SURPASS-PEDS supports use in 17-year-olds 1:
- Most common adverse events were gastrointestinal, all mild to moderate in severity, and decreased over time 1
- Only 6% discontinued due to adverse events (2 patients in the 5 mg group) 1
- No deaths reported during the study period 1
- Safety profile consistent with adults, indicating predictable tolerability 1
Current Guideline Context
While the 2024 ADA guidelines do not yet include tirzepatide (as they predate SURPASS-PEDS), they establish the framework for pharmacologic treatment in youth with type 2 diabetes 2:
- FDA-approved medications for youth with type 2 diabetes previously included only insulin, metformin, and liraglutide (≥10 years) 3
- GLP-1 receptor agonists should be considered when glycemic targets are not met with metformin (with or without basal insulin) in children ≥10 years old 4, 3, 4
- Medications not FDA-approved for youth should not be used outside research trials 4, 3, 4, 5, 3
Clinical Application for a 17-Year-Old
For a 17-year-old with type 2 diabetes:
- Tirzepatide is appropriate if the patient has inadequate glycemic control on metformin and/or basal insulin, based on SURPASS-PEDS evidence 1
- Starting dose is 2.5 mg weekly subcutaneously, with titration to 5 mg or 10 mg based on response and tolerability 1
- Monitor for gastrointestinal side effects (nausea, vomiting, diarrhea), which are typically mild-to-moderate and decrease over time 1
- Contraindicated if family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 4, 3, 4
Important Caveats
For obesity without diabetes in a 17-year-old, the evidence is less clear:
- Mexican guidelines and other obesity management guidelines focus on adults ≥18 years 6
- SURPASS-PEDS specifically studied type 2 diabetes, not obesity alone 1
- Use for obesity without diabetes in adolescents would still be off-label and should await further pediatric obesity trials
Tirzepatide represents a significant advance over previously available options (metformin, liraglutide, insulin) given its dual GIP/GLP-1 mechanism and superior efficacy demonstrated in SURPASS-PEDS 1.